{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T01:21:30Z","timestamp":1792027290661,"version":"4.4.0"},"reference-count":53,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Immune checkpoint inhibitor (ICI) monotherapy with pembrolizumab and ICI plus chemotherapy have been approved as first-line treatments for non\u2013small cell lung cancer (NSCLC) for patients with a programmed cell death ligand\u20131 (PD-L1) tumor proportion score (TPS) of 50% or more, but the choice between these 2 therapeutic options is unclear.<\/jats:p><\/jats:sec>Objective<\/jats:title>To clarify the association of a history of concurrent medication use with treatment outcomes for ICIs with or without chemotherapy in patients with NSCLC with a high PD-L1 TPS and to determine whether these clinical histories are biomarkers for appropriate treatment selection.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This retrospective, multicenter cohort study at 13 hospitals in Japan included patients with advanced NSCLC with a PD-L1 TPS of 50% or more who had received pembrolizumab ICI monotherapy or ICI plus chemotherapy as the initial treatment between March 2017 and December 2020. The median (IQR) follow-up duration was 18.5 (9.2-31.2) months. Data were analyzed from April 2022 through May 2023.<\/jats:p><\/jats:sec>Exposure<\/jats:title>ICI monotherapy with pembrolizumab or ICI plus chemotherapy as first-line treatment.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The primary analysis was the association of treatment outcomes with baseline patient characteristics, including concomitant drug history, after propensity score matching. Cox proportional hazard models were used to determine the associations of patient characteristics with survival outcomes. Logistic regression analysis was used to determine the association of concomitant medication history with treatment outcomes and other patient characteristics.<\/jats:p><\/jats:sec>Results<\/jats:title>A total of 425 patients with NSCLC were enrolled in the study including 271 patients (median [range] age, 72 [43-90] years; 215 [79%] men) who were treated with pembrolizumab monotherapy as the first-line treatment and 154 patients (median [range] age, 69 [36-86] years; 121 [79%] men) who were treated with ICI plus chemotherapy as the first-line treatment. In multivariable analysis, a history of proton pump inhibitor (PPI) use was independently associated with shorter progression-free survival (PFS) in the pembrolizumab monotherapy group (hazard ratio [HR], 1.38; 95% CI, 1.00-1.91; P<\/jats:italic>\u2009=\u2009.048), but not in the ICI plus chemotherapy group. In patients with a PPI history, both the median (IQR) PFS (19.3 [9.0 to not reached] months vs 5.7 [2.4 to 15.2] months; HR, 0.38; 95% CI, 0.20-0.72; P<\/jats:italic>\u2009=\u2009.002) and the median (IQR) overall survival (not reached [9.0 months to not reached) vs 18.4 [10.5 to 50.0] months; HR, 0.43; 95% CI, 0.20-0.92; P<\/jats:italic>\u2009=\u2009.03) were significantly longer in the ICI plus chemotherapy group than in the pembrolizumab monotherapy group. In patients without a history of PPI use, both the median (IQR) PFS (18.8 months [6.6 months to not reached] vs 10.6 months [2.7 months to not reached]; HR, 0.81; 95% CI, 0.56-1.17; P<\/jats:italic>\u2009=\u2009.26) and the median (IQR) overall survival (not reached [12.6 months to not reached] vs 29.9 [13.3 to 54.3] months, HR, 0.75; 95% CI, 0.48-1.18; P<\/jats:italic>\u2009=\u2009.21) did not differ between groups.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>This cohort study found that a history of PPI use could be an important clinical factor in treatment decision-making for patients with NSCLC with a PD-L1 TPS of 50% or more.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2023.22915","type":"journal-article","created":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T15:00:56Z","timestamp":1689087656000},"page":"e2322915","source":"Crossref","is-referenced-by-count":33,"title":["Concomitant Proton Pump Inhibitor Use With Pembrolizumab Monotherapy vs Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With Non\u2212Small Cell Lung Cancer"],"prefix":"10.1001","volume":"6","author":[{"given":"Hayato","family":"Kawachi","sequence":"first","affiliation":[{"name":"Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadaaki","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motohiro","family":"Tamiya","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiki","family":"Negi","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and Hematology, School of Medicine, Hyogo Medical University, Nishinomiya, Hyogo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Goto","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Fujita Health University School of Medicine, Toyoake, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Nakao","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Fukuoka University Hospital, Nanakuma, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinsuke","family":"Shiotsu","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Tanimura","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Japanese Red Cross Kyoto Daini Hospital, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Takeda","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Japanese Red Cross Kyoto Daini Hospital, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asuka","family":"Okada","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Saiseikai Suita Hospital, Suita, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taishi","family":"Harada","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Fukuchiyama City Hospital, Fukuchiyama, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Date","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, Kyoto Chubu Medical Center, Nantan, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Chihara","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Uji-Tokushukai Medical Center, Uji, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isao","family":"Hasegawa","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Saiseikai Shigaken Hospital, Rittou, Shiga, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyo","family":"Tamiya","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Rakuwakai Otowa Hospital, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Ishida","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Katayama","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Morimoto","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Iwasaku","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinsaku","family":"Tokuda","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kijima","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and Hematology, School of Medicine, Hyogo Medical University, Nishinomiya, Hyogo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Takayama","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2023,7,11]]},"reference":[{"issue":"17","key":"zoi230678r1","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non\u2013small-cell lung cancer.","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"zoi230678r2","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer.","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"issue":"10066","key":"zoi230678r3","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet"},{"issue":"19","key":"zoi230678r4","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1\u2013positive non\u2013small-cell lung cancer.","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"issue":"14","key":"zoi230678r5","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","article-title":"Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC.","volume":"383","author":"Herbst","year":"2020","journal-title":"N Engl J Med"},{"issue":"10274","key":"zoi230678r6","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/S0140-6736(21)00228-2","article-title":"Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial.","volume":"397","author":"Sezer","year":"2021","journal-title":"Lancet"},{"issue":"21","key":"zoi230678r7","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer.","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N Engl J Med"},{"issue":"24","key":"zoi230678r8","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC.","volume":"378","author":"Socinski","year":"2018","journal-title":"N Engl J Med"},{"issue":"21","key":"zoi230678r9","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1200\/JCO.21.00174","article-title":"Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score = 50.","volume":"39","author":"Reck","year":"2021","journal-title":"J Clin Oncol"},{"issue":"22","key":"zoi230678r10","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non\u2013small-cell lung cancer.","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"issue":"7","key":"zoi230678r11","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/S1470-2045(19)30167-6","article-title":"Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.","volume":"20","author":"West","year":"2019","journal-title":"Lancet Oncol"},{"issue":"4","key":"zoi230678r12","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.jtho.2020.11.025","article-title":"Atezolizumab plus chemotherapy for first-line treatment of nonsquamous NSCLC: results from the randomized phase 3 IMpower132 trial.","volume":"16","author":"Nishio","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"11","key":"zoi230678r13","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1200\/JCO.22.01989","article-title":"Pembrolizumab plus pemetrexed and platinum in nonsquamous non-small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study.","volume":"41","author":"Garassino","year":"2023","journal-title":"J Clin Oncol"},{"issue":"11","key":"zoi230678r14","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1200\/JCO.22.01990","article-title":"Pembrolizumab plus chemotherapy in squamous non-small-cell lung cancer: 5-year update of the phase III KEYNOTE-407 study.","volume":"41","author":"Novello","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"zoi230678r15","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/cdd.2013.67","article-title":"Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer.","volume":"21","author":"Bracci","year":"2014","journal-title":"Cell Death Differ"},{"issue":"16","key":"zoi230678r16","doi-asserted-by":"publisher","first-page":"9000","DOI":"10.1200\/JCO.2022.40.16_suppl.9000","article-title":"Outcomes of anti\u2013PD-(L)1 therapy with or without chemotherapy (chemo) for first-line (1L) treatment of advanced non\u2013small cell lung cancer (NSCLC) with PD-L1 score = 50%: FDA pooled analysis.","volume":"40","author":"Akinboro","year":"2022","journal-title":"J Clin Oncol"},{"issue":"5","key":"zoi230678r17","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.annonc.2022.02.008","article-title":"Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small-cell lung cancer (Nsq-NSCLC) with PD-L1-high expression using real-world data.","volume":"33","author":"P\u00e9rol","year":"2022","journal-title":"Ann Oncol"},{"issue":"3","key":"zoi230678r18","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.cllc.2023.02.007","article-title":"Chemoimmunotherapy vs. immunotherapy for first line treatment of advanced non-small cell lung cancer with a PD-L1 expression =50% or =90.","volume":"24","author":"Shah","year":"2023","journal-title":"Clin Lung Cancer"},{"issue":"4","key":"zoi230678r19","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.annonc.2020.01.006","article-title":"Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials.","volume":"31","author":"Chalabi","year":"2020","journal-title":"Ann Oncol"},{"issue":"2","key":"zoi230678r20","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001361","article-title":"Integrated analysis of concomitant medications and oncological outcomes from PD-1\/PD-L1 checkpoint inhibitors in clinical practice.","volume":"8","author":"Cortellini","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"4","key":"zoi230678r21","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002421","article-title":"Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy.","volume":"9","author":"Cortellini","year":"2021","journal-title":"J Immunother Cancer"},{"key":"zoi230678r22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.716317","article-title":"Impact of antibiotics and proton pump inhibitors on efficacy and tolerance of anti-PD-1 immune checkpoint inhibitors.","volume":"12","author":"Giordan","year":"2021","journal-title":"Front Immunol"},{"key":"zoi230678r23","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.ejca.2022.06.002","article-title":"Antibiotic-dependent effect of probiotics in patients with non-small cell lung cancer treated with PD-1 checkpoint blockade.","volume":"172","author":"Takada","year":"2022","journal-title":"Eur J Cancer"},{"issue":"20","key":"zoi230678r24","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"2","key":"zoi230678r27","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3322\/caac.21388","article-title":"The eighth edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more \"personalized\" approach to cancer staging.","volume":"67","author":"Amin","year":"2017","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"zoi230678r28","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1007\/s10147-019-01431-z","article-title":"The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV.","volume":"24","author":"Akamatsu","year":"2019","journal-title":"Int J Clin Oncol"},{"issue":"28","key":"zoi230678r29","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1200\/JCO.2018.79.0006","article-title":"Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer.","volume":"36","author":"Arbour","year":"2018","journal-title":"J Clin Oncol"},{"issue":"3","key":"zoi230678r30","doi-asserted-by":"publisher","first-page":"546","DOI":"10.3390\/cancers12030546","article-title":"Association of steroids use with survival in patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.","volume":"12","author":"Petrelli","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"22","key":"zoi230678r31","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1200\/JCO.19.00189","article-title":"Immune checkpoint inhibitor outcomes for patients with non-small-cell lung cancer receiving baseline corticosteroids for palliative versus nonpalliative indications.","volume":"37","author":"Ricciuti","year":"2019","journal-title":"J Clin Oncol"},{"issue":"12","key":"zoi230678r32","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1001\/jamaoncol.2019.2785","article-title":"Association of prior antibiotic treatment with survival and response to immune checkpoint inhibitor therapy in patients with cancer.","volume":"5","author":"Pinato","year":"2019","journal-title":"JAMA Oncol"},{"key":"zoi230678r33","doi-asserted-by":"publisher","first-page":"X40","DOI":"10.1093\/annonc\/mdy511.001","article-title":"Proton pump inhibitors negatively impact survival of PD-1 inhibitor based therapies in metastatic melanoma patients.","volume":"29","author":"Homicsko","year":"2018","journal-title":"Ann Oncol"},{"issue":"2","key":"zoi230678r34","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"2","key":"zoi230678r35","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1046\/j.1365-2036.2001.00904.x","article-title":"Meta-analysis of randomized controlled trials comparing standard clinical doses of omeprazole and lansoprazole in erosive oesophagitis.","volume":"15","author":"Sharma","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"zoi230678r36","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1111\/apt.2005.21.issue-6","article-title":"Meta-analysis: proton-pump inhibition in high-risk patients with acute peptic ulcer bleeding.","volume":"21","author":"Bardou","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"zoi230678r37","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/ajg.2005.100.issue-1","article-title":"Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease.","volume":"100","author":"DeVault","year":"2005","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"zoi230678r38","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1111\/apt.15604","article-title":"Systematic review: the effects of proton pump inhibitors on the microbiome of the digestive tract\u2014evidence from next-generation sequencing studies.","volume":"51","author":"Macke","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"zoi230678r39","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1136\/gutjnl-2015-310861","article-title":"Proton pump inhibitors alter the composition of the gut microbiota.","volume":"65","author":"Jackson","year":"2016","journal-title":"Gut"},{"issue":"6371","key":"zoi230678r40","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1126\/science.aan4236","article-title":"Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients.","volume":"359","author":"Gopalakrishnan","year":"2018","journal-title":"Science"},{"issue":"6371","key":"zoi230678r41","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1126\/science.aao3290","article-title":"The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients.","volume":"359","author":"Matson","year":"2018","journal-title":"Science"},{"issue":"6","key":"zoi230678r42","doi-asserted-by":"publisher","first-page":"847","DOI":"10.21037\/tlcr","article-title":"The role of the gut microbiome on the efficacy of immune checkpoint inhibitors in Japanese responder patients with advanced non-small cell lung cancer.","volume":"8","author":"Katayama","year":"2019","journal-title":"Transl Lung Cancer Res"},{"issue":"8","key":"zoi230678r43","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1016\/j.jtho.2019.04.007","article-title":"The diversity of gut microbiome is associated with favorable responses to anti-programmed death 1 immunotherapy in Chinese patients with NSCLC.","volume":"14","author":"Jin","year":"2019","journal-title":"J Thorac Oncol"},{"issue":"1","key":"zoi230678r44","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/s41416-021-01606-4","article-title":"Efficacy of first-line atezolizumab combination therapy in patients with non-small cell lung cancer receiving proton pump inhibitors: post hoc analysis of IMpower150.","volume":"126","author":"Hopkins","year":"2022","journal-title":"Br J Cancer"},{"issue":"4","key":"zoi230678r45","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1053\/j.gastro.2022.06.070","article-title":"Population-level metagenomics uncovers distinct effects of multiple medications on the human gut microbiome.","volume":"163","author":"Nagata","year":"2022","journal-title":"Gastroenterology"},{"issue":"17","key":"zoi230678r46","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1001\/jama.2015.13766","article-title":"Trends in prescription drug use among adults in the United States from 1999-2012.","volume":"314","author":"Kantor","year":"2015","journal-title":"JAMA"},{"issue":"1","key":"zoi230678r47","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1053\/j.gastro.2017.04.047","article-title":"Complications of proton pump inhibitor therapy.","volume":"153","author":"Vaezi","year":"2017","journal-title":"Gastroenterology"},{"issue":"12","key":"zoi230678r48","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/nrgastro.2017.117","article-title":"Proton-pump inhibitors: understanding the complications and risks.","volume":"14","author":"Malfertheiner","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"7634","key":"zoi230678r49","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1136\/bmj.39406.449456.BE","article-title":"Overprescribing proton pump inhibitors.","volume":"336","author":"Forgacs","year":"2008","journal-title":"BMJ"},{"issue":"4","key":"zoi230678r50","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1053\/j.gastro.2021.12.247","article-title":"AGA clinical practice update on DE-prescribing of proton pump inhibitors: expert review.","volume":"162","author":"Targownik","year":"2022","journal-title":"Gastroenterology"},{"key":"zoi230678r51","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.lungcan.2019.07.004","article-title":"Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies.","volume":"135","author":"Nosaki","year":"2019","journal-title":"Lung Cancer"},{"key":"zoi230678r52","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.904644","article-title":"Pembrolizumab monotherapy for untreated PD-L1-positive non-small cell lung cancer in the elderly or those with poor performance status: a prospective observational study.","volume":"12","author":"Shiotsu","year":"2022","journal-title":"Front Oncol"},{"key":"zoi230678r53","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.3389\/fmicb.2017.01162","article-title":"Geography, ethnicity or subsistence-specific variations in human microbiome composition and diversity.","volume":"8","author":"Gupta","year":"2017","journal-title":"Front Microbiol"},{"key":"zoi230678r26","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-40618-3","volume-title":". AJCC Cancer Staging Manual (8th Edition)","author":"Amin","year":"2017"},{"key":"zoi230678r25","unstructured":"World Health Organization?. Handbook for good clinical research practice (?GCP)?: guidance for implementation. 2005. Accessed May 31, 2023. https:\/\/apps.who.int\/iris\/handle\/10665\/43392"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2807132\/kawachi_2023_oi_230678_1688156388.37561.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T15:01:01Z","timestamp":1689087661000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2807132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,11]]},"references-count":53,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.22915","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,11]]}}}